Similarly, rapamycin failed to attenuate progression of kidney and liver lesions in the PCK rat in vivo, although the activation of Akt/mTOR pathway has been observed in patients with ARPKD [14], [15]. The gene discussed is MTOR; the disease is autosomal recessive polycystic kidney disease.